FOXO Technologies Inc.

FOXO Technologies, Inc. develops genetic sequencing technology artificial intelligence and bioinformatics tools. The company is headquartered in Minneapolis, MN.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment refers to the research and development and is commercializing proprietary epigenetic biomarker technology. The FOXO Life segment is involved in combining life insurance with a dynamic molecular health and wellness platform. The company was founded in 2020 and is headquartered in Minneapolis, MN.

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated wi.

FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023. “I am very proud of our accomplishments during the second quarter,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “In addition to streamlining our capital structure, we continued to advance our growth initiatives through product expansion and scientific.

FOXO Technologies™ Announces Second Quarter 2023 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced that it will report financial results for the second quarter ended June 30, 2023 after market closes on Thursday, August 10, 2023. Management will host a conference call to discuss second quarter 2023 results and recent business highlights at 3:15 p.m. Central time on Thursday, August 10, 2023. During the call, FOXO management will provide prepa.

FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT

PALO ALTO, Calif. & MINNEAPOLIS, Minn.--(BUSINESS WIRE)--GERO, a leading AI-driven biotechnology company focused on aging and longevity and FOXO Technologies Inc. (NYSEAM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced the commencement of discussions to form a strategic collaboration between the two companies. As a result, FOXO and GERO will seek to develop an AI-driven personalized wellness and longevity recommendation engine based on proprietary epige.

Longevity Biotech Companies GERO and FOXO Technologies™ to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research. FOXO's Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthca.

FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO) ( the “Company”), a leader in commercializing epigenetic biomarkers of health and aging, today announced results of its Annual Meeting of Stockholders held on May 26, 2023 (the “Annual Meeting”), where stockholders voted on and approved eight proposals. At the beginning of the Annual Meeting, there were 17,424,619 shares of Class A Common Stock present or represented by proxy at the Annual Meeting, which represented approximat.

FOXO Technologies Announces Results of Annual Stockholders Meeting

MINNEAPOLIS--(BUSINESS WIRE)--On May 15, 2023 NYSE American LLC (“NYSE American”) provided written notice to FOXO Technologies Inc. (NYSEAM: FOXO) (the “Company” or “FOXO”) that NYSE American had halted trading in the Company's warrants, each exercisable for one share of the Company's Class A common stock at an exercise price per share of $11.50, ticker symbol FOXO WS (the “Warrants”), on NYSE American due to the low trading price of the Warrants. On May 16, 2023, NYSE American provided written.

NYSE American Has Commenced Delisting Proceedings in the FOXO WS warrants of FOXO Technologies Inc.

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of FOXO Technologies Inc. (the “Company”), each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 — ticker symbol FOXO WS — from NYSE American. Trading in the Company's warrants will be suspended immediately. Trading in the Company's Class A common stock — tick.

NYSE American to Commence Delisting Proceedings in Warrants of FOXO Technologies Inc. (FOXO WS) and Suspends Trading Immediately

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO) (“FOXO” or the “Company”), a leader in commercializing epigenetic biomarkers of health and aging, today reported financial results for the first quarter ended March 31, 2023. “The first quarter was a strong start to the year, and I am very pleased by our continued execution in support of our strategic goals,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “We recently announced the launch of our direct-.

FOXO Technologies™ Announces First Quarter 2023 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced the direct-to-consumer launch of its beta version wellness product, the FOXO Longevity Report™. The FOXO Longevity Report combines state-of-the-art epigenetic biotechnology, artificial intelligence, and proprietary algorithms to produce longevity and wellness indicators developed from rich epigenetic datasets.

FOXO Technologies Announces Direct-to-Consumer Launch of Longevity Report Beta Product

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced the resignation of Taylor Fay as Chief Operating Officer of the Company, effective April 28, 2023. “I am extremely proud of our achievements throughout Taylor's tenure at FOXO,” said Tyler Danielson, interim CEO, and Chief Technology Officer at FOXO.

FOXO Technologies™ Announces Resignation of Taylor Fay, Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)---- $FOXO #FOXO--FOXO Technologies Inc. (FOXO) Liable for GWG Holdings, Inc.

FOXO Technologies Inc. (FOXO) Class Acton Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against FOXO Technologies Inc.

SAN DIEGO--(BUSINESS WIRE)---- $FOXO #FOXO--FOXO Technologies Inc. (FOXO) is Potentially Liable for GWG Holdings, Inc.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against FOXO Technologies Inc. (FOXO)

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO) (“FOXO” or the “Company”), a leader in commercializing epigenetic biomarkers of health and aging in life insurance, today reported financial results for the full year ended December 31, 2022 and accompanying business highlights. “I am truly excited with the future we are building,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO.

FOXO Technologies™ Announces Full Year 2022 Financial Results and Recent Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022 after market closes on Thursday, March 30, 2023. Management will host a conference call to discuss fourth quarter and full year 2022 results and recent business highlights at 3:15 p.m. Central time on Thursday, March 30, 2023.

FOXO Technologies Inc. Sets Fourth Quarter and Full Year 2022 Business Update Call for Thursday, March 30, 2023 at 3:15 p.m. CT

Applied UV

Buzzfeed

Use these tips for finding multibagger penny stocks The post How to Spot Multibagger Penny Stocks, 3 Tips and Tricks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Spot Multibagger Penny Stocks, 3 Tips and Tricks

MINNEAPOLIS--( BUSINESS WIRE )--FOXO Technologies Inc. ™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE ™ , has engaged AmSuisse, an insurance brokerage general agency with products and specialty programs throughout the United States, to sell Life Insurance Designed to Keep You Alive™.

FOXO LIFE™ to Begin Distribution Relationship with AmSuisse to Sell Life Insurance Designed to Keep You Alive™

MINNEAPOLIS--( BUSINESS WIRE )--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that the Company has filed its Form 10-Q for the third quarter ended September 30, 2022.

FOXO Technologies Announces Filing of Form 10-Q for the Third Quarter 2022

MINNEAPOLIS--( BUSINESS WIRE )--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that effective November 14, 2022, Jon Sabes has been terminated as Chief Executive Officer and Chairman of the Board of the Company. The Board has appointed Tyler Danielson, Chief Technology Officer of the Company, as Interim Chief Executive Officer, and Bret Barnes as Chairman of the Board. The Company has initiated a search process to identify its next Chief Executive Officer. Mr. Danielson will also continue in his role as Chief Technology Officer.

FOXO Technologies Announces Management Changes and Delays Filing of Form 10-Q

MINNEAPOLIS--( BUSINESS WIRE )--FOXO Technologies Inc. (NYSE_AM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that as of November 9, 2022, Erin Sharoni resigned as Chief Product Officer of the company. The Board thanks Erin for her leadership on the FOXO Longevity Report and wishes her well in her future endeavors.

FOXO Technologies Announces Departure of Chief Product Officer, Erin Sharoni

MINNEAPOLIS--( BUSINESS WIRE )--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it is postponing its earnings conference call.

FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call

MINNEAPOLIS--( BUSINESS WIRE )--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE, signed a managing general agency agreement with Haven Life, the insurance technology arm and wholly-owned subsidiary of MassMutual, a carrier with over 170 years of strength and stability.

FOXO Technologies Announces Agreement With Haven Life

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it will report financial results for the third quarter ended September 30, 2022 after market closes on Monday, November 14, 2022.

FOXO Technologies Inc. Sets Third Quarter 2022 Earnings Call for Monday, November 14, 2022 at 3:15 p.m. CT

Clear Channel Outdoor Holdings

E-Home Household Service Holdings Ltd

Gatos Silver

The Metals Co

Best Penny Stocks For 2022 Penny stocks aren't a safe haven investment

Best Penny Stocks To Buy Right Now? 5 With Big News Today

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE, recruited its first distribution partner, California-based BGA Insurance, to begin rolling out Life Insurance Designed to Keep You Alive™ to agents across the state.

News for FOXO Technologies Inc. Stock (FOXO)